Cybin Inc
(NY:
CYBN
)
0.3150
-0.0099 (-3.05%)
Official Closing Price
Updated: 8:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
July 03, 2024
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.
Via
InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
July 02, 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.
Via
InvestorPlace
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
June 26, 2024
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
June 26, 2024
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now!
Via
Benzinga
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
June 18, 2024
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
February 16, 2024
The TDR Three Key Takeaways:
Via
Benzinga
Analyst Expectations for Cybin's Future
November 17, 2023
Via
Benzinga
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
June 05, 2024
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
Via
Benzinga
Exposures
Product Safety
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
May 09, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
March 30, 2024
Via
Benzinga
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
March 26, 2024
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.
Via
InvestorPlace
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
March 13, 2024
Via
Benzinga
Exposures
Product Safety
3 High-Potential Penny Stocks to Turn $1000 into $1 million
March 10, 2024
U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices.
Via
InvestorPlace
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety
January 23, 2024
Cybin will advance the clinical development of the novel psychedelic molecule CYB004 for generalized anxiety treatment.
Via
Benzinga
Exposures
Product Safety
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
January 10, 2024
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...
Via
Benzinga
Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results
January 09, 2024
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and...
Via
Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
Via
Benzinga
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
December 14, 2023
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight.
Via
InvestorPlace
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
Defense Dept. Funds Ketamine Study For PTSD Treatment
Via
Benzinga
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
December 03, 2023
Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a...
Via
Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
November 23, 2023
Via
Benzinga
Expedia To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Friday
November 17, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.